Tuberous Sclerosis Complex (TSC)

🧠 Standard of Care & Symptoms

Tuberous Sclerosis Complex (TSC) is an autosomal dominant, multi-system genetic disorder characterized by the development of benign tumor-like growths (hamartomas) in the brain, skin, kidneys, heart, and lungs.

• Presentation: Key cutaneous, neurological, and visceral hamartomas.
  • Cutaneous Lesions: Highly distinctive.
    • Hypomelanotic Macules (Ash-Leaf Spots): Flat, pale patches of skin present in over 90% of patients, best visualized using a Wood's lamp.
    • Facial Angiofibromas: Reddish papules composed of fibrous tissue and blood vessels, appearing in a butterfly distribution across the nose and cheeks (formerly called adenoma sebaceum).
    • Shagreen Patches: Leathery, thick connective tissue plaques located on the lower back.
    • Ungual Fibromas (Koenen's Tumors): Smooth, flesh-colored nodules arising from under or adjacent to the fingernails or toenails.
  • Neurological Manifestations: Intractable Epilepsy (affecting > 85% of patients, often beginning as infantile spasms in infancy), developmental delays, intellectual disability, and autism spectrum disorder.
  • Visceral Tumors: Renal angiomyolipomas (benign blood vessel/smooth muscle/fat tumors), cardiac rhabdomyomas (often detected prenatally and regressing with age), and pulmonary lymphangioleiomyomatosis (LAM, in adult females).

🧬 Diagnostics & TSC1/TSC2 Genetic Testing

Diagnosis is established clinically based on major and minor criteria (defined by the International TSC Consensus Group) or confirmed via molecular genetic testing.

• Major Clinical Criteria: Includes ≥ 3 hypomelanotic macules, facial angiofibromas (≥ 3) or ungual fibromas, shagreen patch, multiple retinal nodular hamartomas, cortical dysplasia (tubers), subependymal nodules (SENs), subependymal giant cell astrocytoma (SEGA), cardiac rhabdomyoma, LAM, or renal angiomyolipomas.
• Brain MRI: Critical to evaluate for:
  • Cortical Tubers: Focal areas of abnormal cortical migration and layering, appearing as hyperintense lesions on T2-weighted MRI.
  • SEGAs: Slowly growing tumors near the foramen of Monro that can block CSF flow and cause obstructive hydrocephalus.
• Genetic Testing: Identification of a pathogenic mutation in the **TSC1** or **TSC2** gene is diagnostic.

Molecular Pathology & Rheb/mTORC1 Pathway Hyperactivation

The tumor-like cell growth in TSC is caused by the loss of negative feedback within a key cell-growth pathway:

• TSC1 & TSC2 Genes: The **TSC1** gene (chromosome 9q34) encodes the protein **hamartin**, while the **TSC2** gene (chromosome 16p13) encodes **tuberin**. In healthy tissues, hamartin and tuberin associate to form a stable physical complex.
• mTORC1 Pathway Regulation: The Hamartin-Tuberin complex acts as a GTPase-activating protein (GAP) that selectively targets **Rheb** (Ras homolog enriched in brain). By facilitating the hydrolysis of active Rheb-GTP to inactive Rheb-GDP, the complex suppresses downstream signaling.
• Constitutive mTORC1 Activation: When either TSC1 or TSC2 is mutated and inactivated, Rheb remains bound to GTP, causing chronic, constitutive hyperactivation of **mTOR Complex 1 (mTORC1)**. Active mTORC1 phosphorylates S6K1 and 4E-BP1, driving continuous cell growth, protein synthesis, and the development of hamartomas in multiple organ systems.

💊 mTOR Inhibitors & Seizure Control

Management requires a multidisciplinary approach to monitor visceral tumors, control seizures, and treat skin lesions using target-specific medications.

Targeted mTOR Inhibitor Therapy

• Everolimus (oral): A systemic mTOR inhibitor that binds to FKBP-12 to block mTORC1 activity. Everolimus is FDA-approved to shrink subependymal giant cell astrocytomas (SEGAs) that cannot be surgically resected, to treat growing renal angiomyolipomas, and to reduce refractory seizure frequency.
• Topical Sirolimus (Rapamycin) 1% Gel: Applied directly to the face daily. It blocks localized mTORC1 signaling to shrink and fade facial angiofibromas, avoiding systemic side effects.

Anti-Seizure Therapies

• Vigabatrin: An irreversible inhibitor of GABA transaminase. Vigabatrin is the first-line, gold-standard therapy for infantile spasms in infants with TSC, demonstrating high clearance rates.
• Cannabidiol (Epidiolex): Approved as an adjunctive treatment for seizures associated with TSC.

🔬 Active Clinical Trials

Clinical trials are currently evaluating long-acting topical formulations of sirolimus, earlier everolimus intervention in infants to prevent Epilepsy onset, and novel antiepileptics targeting the mTOR pathway.

🗺️ Next Steps After Diagnosis

If you or a child have recently been diagnosed with Tuberous Sclerosis Complex, coordinate these clinical steps:

1. Order TSC1 and TSC2 Genetic Testing: Confirm the specific genetic mutation to assist in family planning and predict clinical severity.
2. Obtain a Baseline Brain and Kidney MRI: Scan the brain to check for cortical tubers or SEGAs, and screen the kidneys for angiomyolipomas.
3. Consult a Pediatric/Adult Neurologist: Establish a seizure action plan and coordinate baseline electroencephalograms (EEG).
4. Discuss mTOR Inhibitor Therapies: Ask about topical Sirolimus gel for facial rashes and evaluate oral Everolimus if brain/kidney tumors or refractory seizures are present.

❓ Patient FAQ

Q: What is the relation between TSC and the mTOR pathway?
A: In healthy cells, the proteins hamartin (TSC1) and tuberin (TSC2) act together as a brake to keep a cell-growth controller called mTOR in check. In Tuberous Sclerosis, a mutation in either TSC1 or TSC2 breaks this brake. This allows the mTOR pathway to become hyperactive (constantly turned "on"), telling the cells to continuously grow and divide, leading to the formation of benign tumors (hamartomas) in the brain, skin, kidneys, and other organs.

Q: Are the tumors in Tuberous Sclerosis cancerous?
A: No. The vast majority of tumors caused by Tuberous Sclerosis (such as cortical tubers, SEGAs in the brain, angiomyolipomas in the kidneys, and facial angiofibromas) are **benign** (non-cancerous) hamartomas. They do not spread to other organs. However, they can still cause health complications by their size and location (for example, a SEGA growing in the brain can block the flow of cerebrospinal fluid, causing pressure to build up, which requires treatment).